ADRB2 and neoplasm: The authors also show that inhibiting β2-AR signaling pathway by non-selective blocker, propranolol; or using β2-AR−/− MDSC could decrease MDSC accumulation, their immunosuppressive function, and thus increase efficacy of antitumor immune response and inhibition of tumor growth.